Wendy Stock to Induction Chemotherapy
This is a "connection" page, showing publications Wendy Stock has written about Induction Chemotherapy.
Connection Strength
0.436
-
Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909. Haematologica. 2012 Apr; 97(4):579-85.
Score: 0.337
-
Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia. J Clin Oncol. 2021 10 10; 39(29):3261-3272.
Score: 0.041
-
Treatment of Acute Promyelocytic Leukemia in Adults. J Oncol Pract. 2018 11; 14(11):649-657.
Score: 0.034
-
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol. 2014 Jan; 164(2):223-32.
Score: 0.024